Telix (TLX) CEO details ADRs, options and large indirect stake
Rhea-AI Filing Summary
Telix Pharmaceuticals Ltd managing director and Group CEO Christian Behrenbruch has filed an initial statement of holdings, detailing his equity and derivative interests in the company. He holds performance share appreciation rights over 93,114 ordinary shares at an exercise price of 4.9500 (Australian dollars) expiring on April 4, 2027, and further rights over 100,223 ordinary shares at 6.9000 expiring on December 31, 2027. These PSARs were granted in April 2022 and May 2023 and are already vested and exercisable.
Behrenbruch also holds share rights over 2,595 ordinary shares at a zero exercise price, expiring on March 31, 2028, which are likewise vested and exercisable. Indirectly, 20,675,000 ordinary shares are held through Elk River Holdings Pty Ltd, where he is the sole director and shareholder. In addition, he directly owns 400,000 American Depositary Receipts, each convertible into one ordinary share with no expiration date, and 254,006 ordinary shares held directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Performance Share Appreciation Rights (right to buy) | -- | -- | -- |
| holding | Performance Share Appreciation Rights (right to buy) | -- | -- | -- |
| holding | Share Rights | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | American Depositary Receipts | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Footnotes (1)
- Dr. Behrenbruch is the sole director and shareholder of Elk River Holdings Pty Ltd. Each American Depositary Receipt (ADR) is convertible at any time, at the holders election, into one ordinary share of the issuer. The ADRs have no expiration date. The performance share appreciation rights (PSARs) were granted on April 5, 2022 and became vested and exercisable on March 6, 2025. Conversion price is reported in Australian Dollars. The PSARs were granted on May 30, 2023, and became vested and exercisable on March 12, 2026. The share rights were granted on May 21, 2025, and became vested and exercisable on March 5, 2026.
